GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Jazz Pharmaceuticals

A blockbuster deal announced earlier this week could be a sign of a bright future for cannabidiol-oriented pharmaceutical companies. On Wednesday, cancer therapy developer Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) struck a US$7.2 billion agreement with UK-based GW Pharmaceuticals PLC (NASDAQ:GWPH), makers of childhood epilepsy treatment Epidiolex, the first cannabis-based medicine approved in the US.

Cardiol CEO sees bright future for pharmaceutically produced cannabidiol after blockbuster Jazz-GW Pharmaceutical deal

Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.

Cannabis ETFs Spike on Jazz-GW Pharma Deal

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GW Pharmaceuticals plc (NASDAQ: GWPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...

INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - GWPH, VIE, FLIR, SNCA

WILMINGTON, Del., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ GM: GWPH) regarding possible breaches of fiduciary duties and other violations of law related to GW Pharmaceuticals' agreement to be acquired by Jazz Pharmaceuticals plc (“Jazz Pharmaceuticals”) (NASDAQ GS: JAZZ). Under the terms of the agreement, GW Pharmaceuticals' shareholders will receive $20.00 worth of shares of Jazz Pharmaceuticals and $200.00 in cash per share.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GW Pharmaceuticals plc Buyout

Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals, maker of the first epilepsy drug derived from marijuana, for $7.2 billion in cash and stock.

Cannabis Stocks Pop on News of Jazz-GW Merger

NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc ("GWPH" or the "Company") (NASDAQ: GWPH) in connection with the proposed acquisition of the Company by...

SHAREHOLDER ALERT: WeissLaw LLP Investigates GW Pharmaceuticals plc

The deal to buy GW Pharmaceuticals creates a leader in neuroscience.

Jazz Pharmaceuticals to Acquire Cannabis Drug Company

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether GW Pharmaceuticals plc (NASDAQ: GWPH) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of GW Pharmaceuticals to Jazz Pharmaceuticals plc for $200.00 in cash and $20.00 in Jazz ordinary shares for each GW American Depositary Share (ADS). On behalf of GW Pharmaceuticals shareholders, Halp

GWPH Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GW Pharmaceuticals plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GWPH

Aurora Cannabis

Canopy Growth

Cronos Group

Tilray Brands

Cannabis stocks rallied anew on Wednesday, spurred on by news of a $7 billion deal for the first company to win U.S. regulatory approval for a cannabis-based drug, a move that's expected to boost investor interest in the plant and its medical benefits.

Cannabis Watch: Cannabis stocks rally anew as $7 billion GW Pharma deal spurs interest in weed and its medical benefits

Aphria

In a quiet market, marijuana companies stood out.

Pot Stocks Are Wednesday's Big Stock Market Winners. Will They Disappoint Shareholders in the End?

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GW Pharmaceuticals plc (NASDAQ: GWPH) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Jazz Pharmaceuticals plc (NASDAQ: JAZZ).

GW PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of GWPH and Encourages Investors to Contact the Firm

GW Pharmaceuticals (GWPH) stock is soaring higher on Wednesday following news that Jazz Pharmaceuticals (JAZZ) is acquiring the company. The post GWPH Stock: 12 Things to Know About the GW Pharma-Jazz Pharma Deal appeared first on InvestorPlace.

GWPH Stock: 12 Things to Know About the GW Pharma-Jazz Pharma Deal

Marijuana stocks rallied as Jazz Pharmaceuticals said it would buy GW Pharma. GWPH stock jumped.

Marijuana Stocks Rally As Jazz Pharma Agrees To Buy CBD Maker, Senate Majority Leader Schumer Backs Cannabis Reform

Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding a cannabis-based epilepsy treatment.

Jazz Pharma adds cannabis-based drug in $7.2 billion deal for GW Pharma

Investors cheered an unexpected acquisition of the cannabinoid-focused biotech.

Why GW Pharmaceuticals Stock Is Skyrocketing Today

Dublin-based Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced Wednesday morning that it has agreed to acquire London-based GW Pharmaceuticals PLC (NASDAQ: GWPH) for $220 per American depositary share (ADS).

Cannabis-Derived Drug Maker GW Pharma Acquired by Jazz Pharma for $7.2 Billion

Medical cannabis stocks and stocks of cannabinoid drug companies are rallying big time Wednesday, the catalyst being a multi-billion-dollar buyout in the space.

CBD Drug Makers, Medical Cannabis Stocks Rally On GW Pharma's Big Buyout

GW Pharmaceuticals soared as much as 46% on Wednesday after Jazz Pharma said it would acquire the company for $7.2 billion in cash and stock. GW Pharma develops therapies derived from the marijuana plant. The UK-based company was the first to receive FDA approval for a cannabinoid-based therapy, Epidiolex, which is used to treat seizures in patients one-year and older.

GW Pharmaceuticals soars 46% after Jazz Pharma agrees to $7.2 billion acquisition of the medical-marijuana company (GWPH)

Jazz Pharmaceuticals said Wednesday it will spend $7.2 billion to buy cannabis biotech GW Pharmaceuticals. In early action, GWPH stock soared.

Jazz Agrees To Buy Cannabis-Focused Biotech GW Pharma For $7.2 Billion

The stock price of GW Pharmaceuticals PLC (NASDAQ: GWPH) is trading at over 40% pre-market today as of 8:26 AM ET. This is why it happened.

GWPH Stock Price Increases Over 40% Pre-Market: Why It Happened

In the first big-ticket biopharma M&A of the year, Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced a deal to buy cannabinoid drug company GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH). The Jazz-GW Pharma Deal: Jazz announced a definitive agreement to buy GW Pharma for a total consideration of $220 per ADS in cash and stock, with $200 in cash and $20 in Jazz shares.

Jazz To Acquire Cannabinoid Drug Company GW Pharma For $7.2B

Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per share in cash and $20 in stock for each share owned, or a premium of about 50% over GW's closing price on Tuesday, and 60% over its 30-day volume weighted average price.

Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of...

News for GW Pharmaceuticals Stock (GWPH)